Intelligent Bio Solutions Inc. Announces QabasTech as Exclusive Distributor in Saudi Arabia
Intelligent Bio Solutions Inc. Announces QabasTech as Exclusive Distributor in Saudi Arabia
NEW YORK, July 24, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced QabasTech ("Qabas") as its exclusive distributor in Saudi Arabia. This partnership marks further growth for INBS in the country, aligning with its ambitious infrastructure projects and commitment to improving public safety.
紐約,2024年7月24日(環球新聞專線)——提供智能、快速、非侵入性檢測解決方案的醫療技術公司智能生物解決方案公司(納斯達克股票代碼:INBS)(“INBS” 或 “公司”)今天宣佈QabasTech(“Qabas”)爲其在沙特阿拉伯的獨家分銷商。這種夥伴關係標誌着INBS在該國的進一步發展,與其雄心勃勃的基礎設施項目和改善公共安全的承諾相一致。
Qabas is a leading technology provider in Saudi Arabia with a strong reputation for providing high-quality products and services across various sectors. With a deep understanding of the local market and a commitment to excellence, Qabas is well-positioned to drive the adoption of INBS' innovative drug screening solution in the country.
Qabas是沙特阿拉伯領先的技術提供商,因在各個領域提供高質量的產品和服務而享有很高的聲譽。憑藉對當地市場的深刻了解和對卓越的承諾,Qabas完全有能力推動INBS的創新藥物篩選解決方案在該國得到採用。
"We are very pleased to partner with Qabas as our exclusive distributor in Saudi Arabia," said Harry Simeonidis, President and CEO at INBS. "This collaboration will enable us to bring our innovative drug screening solution to a market actively seeking effective methods to combat drug abuse. Our Intelligent Fingerprinting Drug Screening System will support Saudi Arabia's efforts to maintain safety and security across various sectors."
INBS總裁兼首席執行官哈里·西蒙尼迪斯表示:“我們很高興與Qabas合作,成爲我們在沙特阿拉伯的獨家分銷商。”“這種合作將使我們能夠將我們的創新藥物篩選解決方案推向積極尋求有效方法來打擊藥物濫用的市場。我們的智能指紋識別藥物篩查系統將支持沙特阿拉伯努力維護各行各業的安全保障。”
In recent years, the Saudi Arabian government has launched strict crackdowns on drugs, resulting in numerous arrests and seizures, highlighting the urgency of addressing drug-related issues within the country. The drug screening market in Saudi Arabia presents significant opportunities for INBS, particularly in sectors such as government, military, police, and drug rehabilitation centers.
近年來,沙特阿拉伯政府嚴厲打擊毒品,導致多人被捕和緝獲,凸顯了國內解決毒品相關問題的緊迫性。沙特阿拉伯的藥物篩查市場爲INBS提供了巨大的機遇,特別是在政府、軍隊、警察和戒毒中心等領域。
About Intelligent Bio Solutions Inc.
關於智能生物解決方案公司
Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering innovative, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. Additionally, the Company's biosensor platform has the potential to test for various indications, ranging from immunological conditions to communicable diseases. The Company's current customer segments include construction, manufacturing and engineering, transport and logistics firms, drug treatment organizations, and coroners.
Intelligent Bio Solutions Inc.(納斯達克股票代碼:INBS)是一家提供創新、快速、非侵入性測試解決方案的醫療技術公司。該公司認爲,其智能指紋識別藥物篩選系統將通過指紋汗液分析徹底改變便攜式測試,這有可能在其他領域得到更廣泛的應用。該測試系統設計爲一種衛生且具有成本效益的系統,可篩選最近在工作場所中常見的藥物的使用情況,包括阿片類藥物、可卡因、甲基苯丙胺和大麻。該技術可在幾秒鐘內收集樣本,不到十分鐘即可得出結果,因此對於安全關鍵行業的僱主來說,這將是一個寶貴的工具。此外,該公司的生物傳感器平台有可能測試各種適應症,從免疫學疾病到傳染病。該公司目前的客戶群包括建築、製造和工程、運輸和物流公司、藥物治療組織和驗屍官。
For more information, visit:
欲了解更多信息,請訪問:
Forward-Looking Statements:
前瞻性陳述:
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, Intelligent Bio Solutions Inc.'s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure regulatory approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including "believes," "estimates," "anticipates," "expects," "plans," "projects," "intends," "potential," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, included in Intelligent Bio Solutions' public filings filed with the Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of its date. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
本新聞稿中的一些陳述是1933年《證券法》第27A條、1934年《證券交易法》第21E條和1995年《私人證券訴訟改革法》所指的前瞻性陳述,涉及風險和不確定性。本新聞稿中的前瞻性陳述包括但不限於智能生物解決方案公司。”能夠成功開發和商業化其藥物和診斷測試,通過合作伙伴關係和合作實現商業利益,並獲得監管部門的批准等。儘管Intelligent Bio Solutions Inc.認爲,截至發佈之日,此類前瞻性陳述中反映的預期是合理的,但事實證明,預期可能與此類前瞻性陳述所表達或暗示的結果存在重大差異。Intelligent Bio Solutions Inc.試圖通過術語識別前瞻性陳述,包括 “相信”、“估計”、“預期”、“計劃”、“項目”、“打算”、“潛在”、“可能”、“可能”、“將”、“應該”、“大約” 或其他傳達未來事件或結果不確定性的詞語,以識別這些前瞻性陳述。這些陳述只是預測,涉及已知和未知的風險、不確定性和其他因素,這些因素包含在Intelligent Bio Solutions向美國證券交易委員會提交的公開文件中。本新聞稿中包含的任何前瞻性陳述僅代表截至發佈日期。Intelligent Bio Solutions沒有義務更新本新聞稿中包含的任何前瞻性陳述,以反映其發佈日期之後發生的事件或情況,也沒有義務反映意外事件的發生。
Company Contact:
Intelligent Bio Solutions Inc.
info@ibs.inc
LinkedIn | Twitter
公司聯繫人:
智能生物解決方案公司
info@ibs.inc
領英 | 推特
Investor & Media Contact:
Valter Pinto, Managing Director
KCSA Strategic Communications
PH: (212) 896-1254
INBS@kcsa.com
投資者和媒體聯繫人:
瓦爾特·平託,董事總經理
KCSA 戰略傳播
電話:(212) 896-1254
INBS@kcsa.com
譯文內容由第三人軟體翻譯。